Drug Trial Radar · NCT00426764
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Feb 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Jun 19, 2007
Primary completion
Nov 11, 2010
Study completion May 17, 2018
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
Conditions
- Peripheral T-cell Lymphoma
Interventions
RomidepsinDrug
Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an Independent Review CommitteeTime frame: Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Locations
90 sites in 10 countries. Site status is shown where the registry gives one.
Moore UCSD Cancer Center
La Jolla, California
UCLA Division of Hematology Oncology
Los Angeles, California
University of California, San Francisco
San Francisco, California
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado
Yale University
New Haven, Connecticut
Georgetown University IRB
Washington D.C., District of Columbia
Washington Hospital Center
Washington D.C., District of Columbia
Cancer Centers of Florida, PA
Orlando, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Augusta Oncology Associates, P.C.
Augusta, Georgia
Central Georgia Cancer Care
Macon, Georgia
Cancer Care and Hematology Specialists of Chicagoland
Arlington Heights, Illinois
Hematology Oncology Assoc. of IL Orchard Research LLC
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Consultants in Blood Disorders and Cancer
Louisville, Kentucky
St. Agnes - Medical Center
Baltimore, Maryland
Center for Cancer And Blood Disorders
Bethesda, Maryland
Center for Cancer Research CAMC
Bethesda, Maryland
Tufts Medical Center
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Minnesota Oncology Hematology, PA
Burnsville, Minnesota
St. Joseph Oncology, Inc
Saint Joseph, Missouri
Arch Medical Services
St Louis, Missouri
Nebraska Cancer Specialists
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Columbia University Medical Center
New York, New York
Taussig Cancer Center Cleveland Clinic Foundation
Cleveland, Ohio
Northwest Cancer Specialists, P.C.
Portland, Oregon
Accelerated Community Oncology Research Network Inc ACORN
Memphis, Tennessee
Mamie McFadden Ward Center
Beaumont, Texas
Methodist Charlton Cancer Center
Dallas, Texas
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
Dallas, Texas
El Paso Cancer Treatment Center
El Paso, Texas
Texas Oncology, P.A.-Fort Worth
Fort Worth, Texas
UT MD Anderson Cancer Center
Houston, Texas
Allison Cancer Center
Midland, Texas
US Oncology
Plano, Texas
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.